Paradigm, TissueInformatics deal

The companies will identify biomarkers that signal the presence and progression of chronic liver disease. PDGM will perform metabolomics studies on tissue, urine and plasma to identify disease-specific biochemical profiles, and TissueInformatics will perform automated, quantitative analyses of tissue histopathology to identify disease-specific changes in tissue structure. ...